Sign in to use this feature.

Years

Between: -

Subjects

remove_circle_outline
remove_circle_outline

Journals

Article Types

Countries / Regions

Search Results (1)

Search Parameters:
Keywords = fibreates

Order results
Result details
Results per page
Select all
Export citation of selected articles as:
18 pages, 1425 KiB  
Review
Current Therapies for Cholestatic Diseases
by Nahum Méndez-Sánchez, Carlos E. Coronel-Castillo and Ana L. Ordoñez-Vázquez
Biomedicines 2023, 11(6), 1713; https://doi.org/10.3390/biomedicines11061713 - 15 Jun 2023
Cited by 7 | Viewed by 2809
Abstract
Cholestasis is a condition characterized by decrease in bile flow due to progressive pathological states that lead to chronic cholestatic liver diseases which affect the biliary tree at the intrahepatic level and extrahepatic level. They induce complications such as cirrhosis, liver failure, malignancies, [...] Read more.
Cholestasis is a condition characterized by decrease in bile flow due to progressive pathological states that lead to chronic cholestatic liver diseases which affect the biliary tree at the intrahepatic level and extrahepatic level. They induce complications such as cirrhosis, liver failure, malignancies, bone disease and nutritional deficiencies that merit close follow-up and specific interventions. Furthermore, as those conditions progress to liver cirrhosis, there will be an increase in mortality but also an important impact in quality of life and economic burden due to comorbidities related with liver failure. Therefore, it is important that clinicians understand the treatment options for cholestatic liver diseases. With a general view of therapeutic options and their molecular targets, this review addresses the pathophysiology of cholangiopathies. The objective is to provide clinicians with an overview of the safety and efficacy of the treatment of cholangiopathies based on the current evidence. Full article
(This article belongs to the Special Issue Liver Disease and Therapy)
Show Figures

Figure 1

Back to TopTop